Dr Katharine Carter

Senior Lecturer

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

I have two main areas of research interests: the study of leishmaniasis and drug delivery.  My research on leishmaniasis has been involved in understanding the underlying immunological mechansims involved in the control of the disease, the mechananism responible for drug resistance, and development of novel vaccine fomulations to control the infection.  I work on L. donovani, L. major  and L. mexicana  and we have recently started using luciferase-expressing parasites to track the infection.   My drug delivery studies have focused on using non-ionic surfactant vesicles (NIV) to improve drug delivery by the intravenous or pulmonary routes. We are currently involved in commercialising NIV for the pulmonary delivery ('Inhalosomes') through the spin-out comany 'Inhalosome-C Ltd', which is involved in developing a cisplatin product for the treatment of lung cancer.

B10 Fo luc cells imaged using the IVIS® system

Cells were treated with an anticancer drug (columns 3-10) - with the highest concentration in colum 3 and the lowest in column 10.  Column 2 shows the results for the control cells and column 11 shows the results for the negative control. This type of assay is used for screening anticancer compounds.  


Genomic and metabolomic polymorphism among experimentally selected paromomycin-resistant Leishmania donovani strains
Shaw C D, Imamura H, Downing T, Blackburn G, Westrop G D, Cotton J A, Berriman M, Sanders M, Rijal S, Coombs G H, Dujardin J C, Carter K C
Antimicrobial Agents and Chemotherapy (2019)
IL-4 mediated resistance of BALB/c mice to visceral leishmaniasis is independent of IL-4Rα signaling via T cells
McFarlane Emma, Mokgethi Thabang, Kaye Paul M, Hurdayal Ramona, Brombacher Frank, Alexander James, Carter Katharine C
Frontiers in Immunology Vol 10 (2019)
Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents, and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy
Hlaka Lerato, Rosslee Michael-Jon, Ozturk Mumin, Kumar Santosh, Parihar Suraj, Brombacher Frank, Khalaf Abedawn, Carter Katharine, Scott Fraser, Suckling Colin, Guler Reto
Journal of Antimicrobial Chemotherapy Vol 72, pp. 3334–3341 (2017)
New avenues for drug delivery in Leishmania: using treatment of visceral leishmaniasis with amphotericin B as an exemplar.
Carter Katharine, Mullen Alexander
Drug Discovery in Leishmaniasis (2016) (2016)
An evaluation of minor groove binders as anti-lung cancer therapeutics
Scott Fraser, Khalaf Abedawn, Suckling Colin, Carter Katharine, Grant Mary, Henderson Catherine, Westrop Gareth, Watson David
Bioorganic and Medicinal Chemistry Letters (2016)
Chemical and antimicrobial profiling of propolis from different regions within Libya
Siheri Weam, Zhang Tong, Ebiloma Godwin Unekwuojo, Biddau Marco, Woods Nicola, Hussain Muattaz Yassein, Clements Carol J, Fearnley James, Edrada Ebel RuAngelie, Paget Timothy, Müller Sylke, Carter Katharine C, Ferro Valerie A, De Koning Harry P, Watson David G
PLOS One Vol 11 (2016)

more publications

Professional activities

4th Worldleish Congress on Leishmaniasis 2009 in Lucknow, India
Keynote/plenary speaker

more professional activities


Screening antileishmania drugs
Carter, Katharine (Principal Investigator)
04-Jan-2018 - 31-Jan-2018
Development of a vaccine against leishmaniasis (Vacation Scholarship)
Carter, Katharine (Principal Investigator)
06-Jan-2016 - 17-Jan-2016
Development of starting materials for cell-based treatments (project plan for SMART grant)
Carswell, Hilary (Principal Investigator) Carter, Katharine (Co-investigator) Currie, Susan (Co-investigator) Pickard, Ben (Co-investigator) Williams, Roderick (Co-investigator) McKittrick, Craig (Researcher)
01-Jan-2015 - 31-Jan-2016
Development of a diagnostic test for lesihmaniasis
Carter, Katharine (Principal Investigator)
12-Jan-2013 - 31-Jan-2014
KTA Application: Development of a commercially viable non- ionic surfactant vesicle amphotericin B formulation.
Carter, Katharine (Principal Investigator) Ferro, Valerie (Principal Investigator) Mullen, Alexander (Principal Investigator)
Improve AMB-NIV formulation
08-Jan-2012 - 30-Jan-2012
Knowledge Transfer Account / RA4842
Carter, Katharine (Principal Investigator)
01-Jan-2012 - 30-Jan-2012

more projects


Strathclyde Institute of Pharmacy and Biomedical Sciences
Hamnett Wing

Location Map

View University of Strathclyde in a larger map